Monaco Asset Management SAM purchased a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,069,732 shares of the company’s stock, valued at approximately $1,359,000.
Other institutional investors also recently bought and sold shares of the company. Ieq Capital LLC purchased a new stake in Editas Medicine during the 4th quarter worth about $31,000. Thrive Wealth Management LLC acquired a new position in Editas Medicine in the fourth quarter valued at $36,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Editas Medicine during the third quarter worth about $47,000. Erste Asset Management GmbH purchased a new position in shares of Editas Medicine during the third quarter worth about $52,000. Finally, Drive Wealth Management LLC acquired a new stake in shares of Editas Medicine during the third quarter worth about $65,000. 71.90% of the stock is owned by hedge funds and other institutional investors.
Editas Medicine Trading Down 9.3 %
NASDAQ:EDIT opened at $1.37 on Friday. The firm has a market cap of $113.68 million, a P/E ratio of -0.54 and a beta of 1.88. The stock’s 50 day simple moving average is $1.50 and its 200-day simple moving average is $2.36. Editas Medicine, Inc. has a 12-month low of $1.12 and a 12-month high of $8.59.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. downgraded Editas Medicine from a “neutral” rating to an “underweight” rating in a research note on Monday, December 16th. Bank of America lowered shares of Editas Medicine from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $13.00 to $1.00 in a research report on Monday, November 25th. Truist Financial lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wells Fargo & Company lowered shares of Editas Medicine from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $7.00 to $4.00 in a research report on Wednesday, December 11th. Finally, Evercore ISI lowered their target price on shares of Editas Medicine from $7.00 to $5.00 and set an “outperform” rating on the stock in a research report on Monday, December 16th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $6.83.
Get Our Latest Stock Report on EDIT
Editas Medicine Profile
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Recommended Stories
- Five stocks we like better than Editas Medicine
- Transportation Stocks Investing
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Market Cap Calculator: How to Calculate Market Cap
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What Are Dividend Champions? How to Invest in the Champions
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDIT – Free Report).
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.